Source: WRAL TECHWIRE, 12/13/21

 Brii Biosciences says tests show its combination therapy is “active” against the emerging Omicron variant of COVID, saying it “holds up well.” The company is seeking emergency use authorization for the treatment amubarvimab/romlusevimab. “We believe the amubarvimab/romlusevimab combination has the potential to be a best-in-class treatment option for a broad range of high risk COVID-19 patients. These latest findings underscore that our combination antibody therapy holds up well against the Omicron variant that...

For more of this story, click here.